Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1144]
News [2512]
Articles [153]
Editorials [8]
Conferences [102]
elearning [18]
Why some cancers may respond poorly to key drugs discovered
Why some cancers may respond poorly to key drugs discovered
ESMO 2020: Immunotherapy combination improves outcomes in advanced kidney cancer
ESMO 2020: Immunotherapy combination improves outcomes in advanced kidney cancer
ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer
ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer
ESMO 2020: New first-line treatment option for metastatic kidney cancer, according to results of phase 3 study
ESMO 2020: New first-line treatment option for metastatic kidney cancer, according to results of phase 3 study
Immunotherapy improves survival in advanced bladder cancer patients
Immunotherapy improves survival in advanced bladder cancer patients
Algorithms uncover cancers' hidden genetic losses and gains
Algorithms uncover cancers' hidden genetic losses and gains
Immunotherapy improves survival in advanced bladder cancer patients
Immunotherapy improves survival in advanced bladder cancer patients
Combining two precision medicines can treat drug-resistant cancers
Combining two precision medicines can treat drug-resistant cancers
Proton pump inhibitors may affect responses to atezolizumab in patients with urothelial cancer
Proton pump inhibitors may affect responses to atezolizumab in patients with urothelial cancer
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Combination immunotherapy benefits subset of patients with advanced prostate cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation